Company intelligence / Profile preview

SYDRA

San Francisco, CA, USA

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Sydra is a synthetic biology company developing a programmable biology platform for the next generation of cell and gene therapies. The company focuses on creating biological operating systems that allow for the design and construction of complex biological circuits within cells. By leveraging advanced computational tools and high-throughput experimentation, Sydra aims to engineer cellular therapies with enhanced precision, safety, and efficacy. Their primary therapeutic focus includes oncology and autoimmune diseases, where they seek to overcome the limitations of current CAR-T and CAR-NK cell therapies.

Therapeutic areas: OncologyImmunology
Modalities: Cell therapyGene therapySynthetic biology
Industry: Biotech

Beyond the preview

Go deeper on SYDRA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYDRA.

Explore the full profile